




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |   |   |
|---|--|---|---|
| (51) International Patent Classification <sup>6</sup> :<br><b>A61F 2/02</b>   |  | <b>A1</b>   | (11) International Publication Number: <b>WO 98/46165</b>       |
|   |  |   | (43) International Publication Date: 22 October 1998 (22.10.98) |
| (21) International Application Number: PCT/US98/07072   |  | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). |   |
| (22) International Filing Date: 10 April 1998 (10.04.98)  |  |   |   |
| (30) Priority Data:<br>08/838,852 11 April 1997 (11.04.97) US   |  |   |   |
| (71) Applicant: CRYOLIFE, INC. [US/US]; 1655 Robert Boulevard, N.W., Kennesaw, GA 30144 (US).   |  |   |   |
| (72) Inventors: GOLDSTEIN, Steven; 2939 Greenbrook Way, Atlanta, GA 30345 (US). BLACK, Kirby, S.; 1371 Peppergrass Trail, Acworth, GA 30301 (US). |  |   |   |
| (74) Agent: WILSON, Mary, J.; Nixon & Vanderhye P.C., 8th floor, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).                            |  | <b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>   |   |

(54) Title: TISSUE DECELLULARIZATION

**In Vivo Calcification of Porcine Heart Valve Tissues**

## (57) Abstract

The present invention relates, in general, to tissue decellularization and, in particular to a method of treating tissues, for example, heart valves, tendons and ligaments, so as to render them acellular and thereby limit mineralization and/or immunoreactivity upon implementation *in vivo*.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

## TISSUE DECELLULARIZATION

### TECHNICAL FIELD

The present invention relates, in general, to tissue decellularization and, in particular to a method  
5 of treating tissues, for example, heart valves, ligaments and tendons, so as to render them acellular and thereby limit mineralization and/or immunoreactivity upon implantation *in vivo*.

### BACKGROUND

10 Cardiac valve disorders can be serious and in fact are often fatal. Treatment may require replacement of the valve with a prosthetic valve - mechanical or bioprosthetic. Bioprosthetic valves typically include a leaflet portion and a vascular conduit portion, both  
15 generally of a biological material, and possibly a stent.

While bioprosthetic valves have a number of advantages over mechanical valves, including a lower risk of complications resulting from thrombus formation,  
20 they are associated with a higher risk of mineralization. This increased risk significantly limits the durability of the replacement valve. The present invention provides a method of rendering tissues, including heart valves, resistant to  
25 mineralization while preserving biomechanical properties

of the tissue. The present invention also provides a method of reducing immunoreactivity of transplanted tissues which are not fixed by chemical or physical means, or combinations thereof, prior to implantation.

5

OBJECT AND SUMMARY OF THE INVENTION

It is a general object of the invention to provide a method treating tissue so as to limit mineralization and/or immunoreactivity post implantation.

10 It is another object of the invention to provide a method of decellularizing a tissue and thereby enhancing its durability and/or reducing its immunoreactivity.

It is a further object of the invention to provide a tissue, for example, a heart valve bioprosthesis, that retains mechanical integrity, is resistant to  
15 calcification and is characterized by reduced immunoreactivity upon implantation.

The foregoing objects are met by the present invention which provides a method of effecting decellularization of tissues, including heart valve  
20 tissues (eg leaflets and valve associated vascular conduit). The method comprises contacting the tissue to be decellularized with a hypotonic solution under conditions such that cell lysis occurs, and subsequently  
subjecting the tissue to nuclease treatment under  
25 conditions such that the tissue is rendered histologically acellular.

Further objects and advantages of the present invention will be clear from the description that follows.

#### BRIEF DESCRIPTION OF THE DRAWINGS

5           Figures 1A and B show the effect of decellularization on the extensibility of and elastic modulus of aortic and pulmonary leaflets.

          Figures 2A and B show the effect of decellularization on rates of stress-relaxation of  
10       aortic and pulmonary leaflets.

          Figures 3A, B and C show the effect of decellularization on failure load, maximum stress and elastic modulus of aortic and pulmonary leaflets.

          Figures 4A, B, C and D show the effect of  
15       decellularization on calcification of porcine heart aortic and pulmonary heart valve tissues.

#### DETAILED DESCRIPTION OF THE INVENTION

          The present invention relates, in one embodiment, to a method of rendering a biological tissue acellular.  
20       The method comprises exposing the tissue to a hypotonic solution under conditions such that cell lysis results, and subjecting the resulting tissue to nuclease

treatment so as to remove nucleic acids and associated phosphorous-containing groups which may bind calcium. Nuclease treatment effectively stops cell replication and protein synthesis. In a preferred aspect of this embodiment, the tissue is rendered essentially acellular, the term "essentially" meaning having at least 70% fewer cells than the naturally occurring biological material. The extent of decellularization can be determined histochemically, for example, by staining the tissue with hematoxylin and eosin using standard techniques. Immunohistochemical staining can also be used, for example, to visualize cell specific markers such as smooth muscle actin and histocompatibility antigens - an absence of such markers being a further indication of decellularization.

In accordance with the present method, the biological tissue is, preferably, first washed in a solution of a bioburden reducing agent, such as an antibiotic. The tissue can then be decellularized immediately or it can be cryopreserved. Cryopreserved tissue is thawed prior to decellularization under conditions such that the cryoprotectant is eliminated and toxicity resulting therefrom thereby avoided. Appropriate thawing conditions are well known in the art. The tissue (fresh or thawed cryopreserved) is then placed in hypotonic solution in order to effect cell lysis. Appropriate solutions include water or a solution having a solute (eg a salt such as NaCl) concentration of up to 80 milliosmolar (for example, a

10-20 or 20-40 mM NaCl solution). Lysis can be effected, for example, at a temperature in the range of 30°C to 40°C, preferably 37°C, advantageously in an atmosphere of 5% CO<sub>2</sub>, for example, for about 4 to 5 24 hours. The tissue is then transferred to a nuclease solution (eg DNAase- and/or RNAase-containing) and incubated, for example, at a temperature in the range of about 30°C to 40°C, preferably 37°C, advantageously in an atmosphere of 5% CO<sub>2</sub>, for example, for about 4 to 10 24 hours. Subsequently, the tissue is transferred to a solution that can maintain tissue structural integrity, for example, a physiologically normal (isotonic) solution such as a cell culture medium, eg DMEM. Cell lysis can continue during maintenance of the tissue in 15 the physiologically normal solution and thus the tissue can be removed from the lytic/nuclease solutions before 70% decellularization has been achieved.

Tissues that have been decellularized can be terminally sterilized using any of a variety of 20 sterilants. For example, the tissue can be subjected to gamma irradiation, ethylene oxide, peracetic acid,  $\beta$ -propiolactone, povidone-iodine, or UV irradiation in the presence or absence of photosensitizers. Appropriate conditions for effecting terminal 25 sterilization are well known in the art.

Biological tissues suitable for use in the present method include those appropriate for implantation into humans or animals. Tissues can be human or non-human (eg bovine, porcine or non-human primate) in origin. As

indicated above, the tissues can be fresh or cryopreserved. In either case, the tissue is decellularized prior to any fixation. While the present invention is exemplified by reference to heart valve leaflets, the decellularization method is applicable to other tissues as well, including tendons, ligaments, fascia, arteries, veins, diaphragm, pericardium, umbilical cords, dura mater or tympanic membranes.

Upon completion of decellularization, the biological tissue can be processed and/or fabricated as appropriate depending on the ultimate use of the tissue. Any fixation of the decellularized tissue can be effected using art-recognized techniques, including glutaraldehyde fixation. Unfixed tissue, however, can also be used. Unfixed tissue can be impregnated with any of a variety of agents including those that stimulate recellularization upon implantation of the decellularized tissue *in vivo*. Examples of such agents include growth factors, adhesion factors, such as glycosaminoglycans, and soluble extracellular matrix glycoproteins such as fibronectin, laminin, vitronectin, etc. Other agents that can be used include those that augment hemocompatibility, thrombomodulators, and antibiotics. Appropriate impregnation techniques are known in the art. When the tissue is a heart valve, fabrication with a biological or non-biological stent can be effected using standard protocols.

Bioprostheses produced in accordance with the present invention can be used as replacements for



defective tissues in mammals, particularly humans. Methods of effecting the replacement of, for example, heart valves, tendons, ligaments, vessels, etc., are well known in the art.

5           Tissue decellularized in accordance with the present invention is subject to less mineralization (eg calcification) *in vivo* than non-treated tissue. Decellularization also results in a tissue that is reduced in immunogenicity.

10           Certain aspects of the present invention are described in greater detail in the non-limiting Examples that follow. While the decellularization methodology of the present invention and that of USP 5,595,571 are distinct, it will be appreciated that certain details of  
15           that disclosure are equally applicable here, including source of biological tissues, methods of monitoring extent of decellularization and methods of processing and fabrication post decellularization. Accordingly, USP 5,595,571 is incorporated in its entirety by  
20           reference.

#### EXAMPLE I

##### Decellularization of Leaflets and Whole Values

25           The following solutions are utilized in the protocols that follow:

1M Tris pH 7.6: To 80ml deionized water add  
11.21gm Tris, adjust pH to 7.6 with 1N NaOH and bring  
volume to 100ml and store at 4°C.

5 1M CaCl<sub>2</sub>: To 20ml deionized water add 2.22gm CaCl<sub>2</sub>  
and store at 4°C.

1M MgCl<sub>2</sub>: To 10ml deionized water add 2.033gm MgCl<sub>2</sub>  
and store at 4°C.

10 DNase I Solution: To 4.95ml sterile water add 5ml  
glycerol (final conc 50%), 20mg DNase I (Sigma D5025)  
(final conc 2mg/ml), and 50 µl 1M CaCl<sub>2</sub> (final conc  
5 mM). Aliquot 1ml to chilled labeled 1.5ml microfuge  
tubes and store at -20°C.

15 RNase A Solution: To 10ml sterile water add 100mg  
RNase A, and mix to dissolve. Aliquot 500µl of solution  
to each of 20 prechilled 1.5ml microfuge tubes and store  
at -20°C.

20 Nuclease Solution: To 93.66ml sterile water, add  
4.8ml 1M Tris pH 7.6 (final 48mM), 288µl 1M MgCl<sub>2</sub> (final  
conc 2.88mM), 96µl 1M CaCl<sub>2</sub> (final conc .96mM), filter  
sterilize using 0.2 micron filter, add 960µl 2mg/ml  
DNase I (final conc 19.2 µg/ml) 192µl 10mg/ml RNase A  
(final conc 19.2 µg/ml).

Decellularization of leaflets

## DAY 1

A valve is removed from a liquid nitrogen freezer and submerged in a 37°C water bath for approximately 15 min. Under sterile conditions, the valve is removed from the packaging and placed in a sterile 7oz. specimen cup with approximately 50ml of lactate-ringer 5% dextrose (LRD5) solution for 15 min. at room temperature. The valve is dissected by making a single cut down the commissure located between the left and right coronary arteries. The valve is laid open with the mitral valve leaflet up, the left coronary leaflet to the left, the right coronary leaflet to the right, and the non-coronary leaflet in the middle. The leaflets are dissected free of the valve as close to the conduit wall as possible and placed in separate labeled 15ml conical centrifuge tubes filled with 10ml LRD5 solution for 10 minutes at room temperature. The leaflets are moved to second labeled 15ml conical centrifuge tubes filled with 10ml LRD5 solution and allowed to stand for 10 minutes at room temperature. The leaflets then are moved to third labeled 15ml conical centrifuge tubes filled with 10ml sterile water and placed in an incubator at 37°C 5% CO<sub>2</sub> for 2 hours. The leaflets are placed in 6-well culture plates and weighted down with sterile glass rings. 5 ml nuclease solution is added to each well and the leaflets incubated overnight at 37°C 5% CO<sub>2</sub>.

## DAY 2

The nuclease solution is removed and 5ml of DMEM is added to each well and the leaflets are returned to the incubator.

## 5 DAY 3-16

The medium is changed every other day for two weeks.

Alternative procedure for whole valves

10 If valves have been cryopreserved, they are thawed and washed as above; if valves are fresh, they are washed once in 80ml of LRD5 for 15 minutes in a 7oz sterile specimen cup.

15 After the valve is washed, it is transferred to a 7oz sterile specimen cup containing about 80ml of sterile H<sub>2</sub>O and placed in the 37°C 5% CO<sub>2</sub> incubator for 4 hours.

The valve is removed to a 7oz sterile specimen cup containing about 80ml nuclease solution and returned to the incubator overnight.

## 20 DAY 2

The valve is removed to a 7oz sterile specimen cup containing about 80ml (ALT+) solution (containing netilmicin, 54µg/ml; lincomycin, 131µg/ml; cefotaxime, 145µg/ml; vancomycin, 109µg/ml; rifampin, 65µg/ml; 25 fluconazole, 100µg/ml; and amphotericin B, 84µg/ml).

## DAY 3-16

The medium is changed every other day for two weeks using ALT+ solution for the first week and DMEM for the second.

- 5           The foregoing procedures are open culture procedures. Thus the specimen cup lids are loosened when placed in the incubator.

## EXAMPLE II

Experimental details:

- 10           *Porcine heart valves.* Porcine hearts were obtained from market weight pigs (> 120 kg). After rinsing in sterile phosphate buffered saline, the hearts were field dissected (apex removed) and shipped at 4°C in sterile PBS. All hearts arrived within 24 hr of animal
- 15           slaughter. Aortic and pulmonary valves were dissected as roots. These tissues were subjected to a bioburden reduction step of incubation in a mixture of antibiotics and antimycotics for 48 hr at 48°C. The disinfected tissues were either cryopreserved (10% (v/v) DMSO and
- 20           10% (v/v) fetal bovine serum, -1°C/min) or were decellularized by a procedure involving treatment with hypotonic medium followed by digestion with a mixture of deoxyribonuclease I and ribonuclease A. After 12 days, the decellularized valves were either cryopreserved as
- 25           above or chemically fixed in 0.35% (w/v) glutaraldehyde

at 2 mmHg in phosphate buffered saline (pH 7.4) for a total of 7 days; the low pressure fixation ensures maintenance of the natural crimp of the collagen matrix. The fixed tissues were not cryopreserved, but were  
5 stored in 0.35% glutaraldehyde solution.

Prior to any examination (calcification, biomechanics, histology), the cryopreserved tissues were thawed rapidly to prevent ice-recrystallization by immersion of the packaged tissue in a 37°C water bath.  
10 Cryopreservation medium was eluted from the thawed valves with 500 ml of lactated-Ringers solution containing 5% dextrose. The glutaraldehyde-fixed tissues were washed three times each with 200 ml of normal saline.

15 *In vivo static calcification.* Calcification of treated tissues was assessed in vivo by subdermal implantation in rats. Weanling male, Sprague-Dawley rats were obtained from Charles Rivers Laboratories. After one week equilibration, animals averaged  $136 \pm 18$   
20 g in weight. The heart valves were dissected to provide aortic and pulmonary leaflets and vascular conduit sections, each 0.5 cm square. With the rats under ketamine and xylazine (10 mg/kg and 5 mg/kg, respectively, IP) anesthesia, and following preparation  
25 of a sterile field, 2 cm diameter pouches were formed in the dorsal subcutaneous, four per animal, and sections of tissues inserted. Incisions

were closed with stainless steel staples. The rats were allowed to recover and were then permitted free access to food and water. Tissue samples were recovered at 1, 2, and 4 months post-implantation for  
5 determination of calcium content.

*Method for calcium determination in tissue samples.*  
Recovered tissues were washed in sterile calcium and magnesium-free phosphate buffered saline, three times 10 ml each. Wet weight was measured, and after mincing,  
10 the pieces were dried overnight in a centrifugal evaporator (Savant Speed-Vac). After recording dry weight the tissues were digested in 10 ml of 25% (v/v) HNO<sub>3</sub> for at least 24 hr at 70°C. An aliquot of the digest solution was diluted 10-fold in 0.2 N HCl  
15 containing 1% (w/v) lanthanum nitrate. Finally, calcium content was measured using a Perkin-Elmer 300 atomic absorption spectrometer calibrated with a certified calcium standard from SPEX Plasma Standards (Cat. PLCA2-3Y. Response in this system was linear between  
20 0.2-20 µg/ml.

*Biomechanics testing.* Aortic and pulmonary leaflets were die cut in the circumferential dimension to provide "dog-bone"-shaped specimens, 0.5 cm wide at midsubstance. Thickness of each sample was derived from  
25 the average of three measurements taken with a low mass pin attached to a conductance circuit and digital

caliper. Leaflets were mounted in specially designed clamps with a standard gauge length of 1 cm. All testing was carried out with the tissue in Hank's balanced salt solution maintained at  $37 \pm 2^\circ\text{C}$ . Each specimen was preconditioned to a load of 150 g until successive load-elongation curves were superimposable (~20 cycles). The following measurements were then taken: 1) low-load elongation to derive stress-strain relationships while imposing up to 150 g load on the tissue at an extension rate of 10 mm/min, a rate which reflects previously reported studies of leaflet biomechanics (Leesson-Dietrich et al, J. Heart Valve Disease 4:88 (1995)); 2) examination of viscoelastic properties of the specimens in a stress-relaxation study (tissue elongated to a load of 150 g and following residual loads for up to 1000 sec) - both the % of initial load remaining at these time points as well as the rate of stress-relaxation (i.e., the slope of the percent stress remaining versus time) were determined; and 3) ultimate uniaxial tensile testing to tissue failure. At least 8 specimens of each tissue type were examined.

*Histochemistry.* Samples of fresh and explanted tissues were immersed in 10% sucrose solution for 4-18 hr at  $4^\circ\text{C}$ . After brief fixation in 10% formalin, the pieces were placed in molds and frozen in OCT using a liquid nitrogen bath. Cryosections, 6-10  $\mu\text{m}$  thick, were cut using an IEC cryostat (Needham Heights, MA).



Sections were then stained either with hematoxylin and eosin or stained specifically for calcium according to the method of von Kossa (Theory and Practice of Histological Techniques, edited by Bancroft and Stephens, Churchill Livingstone, Edinburgh (1990)).  
5 Sections were viewed and photographed using a Nikon Optiphot microscope.

*Statistics.* Statistical differences in the group means of biomechanical parameters was assessed by  
10 independent t-tests. A p value of 0.05 was chosen as the level of significant differences. Calcium data were analyzed according to ANOVA testing carried out with the statistical program for the IBM-PC, SPSS-PC.

### Results

15 *Biomechanics.* Low load testing - extensibility and low modulus. The biomechanical properties of strips of aortic and pulmonary porcine heart valve leaflets were compared between fresh-cryopreserved and decellularized-cryopreserved tissues. Fresh aortic and pulmonary  
20 leaflets were found to have significant differences in extensibility; pulmonary leaflets had extension 2.3-fold greater than aortic leaflets ( $p < 0.01$ ). However, the elastic modulus of these tissues were not different pre-decellularization ( $10.6 \pm 1.1$  vs.  $9.15 \pm 0.64$ ,  $p = 0.255$ ,  
25 Fig. 1). With decellularization, the extensibility of the two leaflet type became indistinguishable ( $30.4 \pm 2.5$

vs.  $30.2 \pm 3.3$ ,  $p=0.981$ ). The elastic modulus of the aortic leaflets was unchanged by decellularization ( $p=ns$  (not significant)), as compared to the fresh tissue).

5 In contrast, pulmonary leaflet tissues was markedly stiffened by decellularization, with the elastic modulus rising by 660%, ( $p<0.05$ ). As a result, the elastic modulus of decellularized pulmonary tissue was 550% greater than that of the decellularized aortic leaflet.

10 *Stress-relaxation testing.* The initial (10 sec) and the final (1,000 sec) rates of stress-relaxation for fresh aortic and pulmonary leaflets were comparable and not statistically different ( $p=0.103$  and  $p=0.115$ , respectively, Fig. 2). For decellularized tissues, only the initial rate of stress-relaxation or  
15 aortic leaflets was obtained; this was no different from the fresh tissue value. The increased stiffening of the pulmonary leaflets with decellularization which was observed with low-load testing was reflected by a higher final level of stress remaining (increase from  
20  $64.1 \pm 2.18\%$  to  $81.5 \pm 2.5\%$ ). The relaxation slope for the pulmonary leaflets were reciprocally changed by decellularization, decreasing from  $9.8 \pm 0.8$  in the fresh tissue to  $4.7 \pm 1.5$  in the treated tissue.

25 Ultimate tensile testing - failure load, maximum stress, and elastic modulus (Fig. 3). In fresh tissues the aortic leaflets failed a twice the load as did the pulmonary valve tissue ( $p<0.001$ ). However, there

was no statistical difference maximum stress at failure of the aortic and pulmonary leaflets ( $8.0 \pm 1.2$  MPa vs.  $6.0 \pm 0.9$ ,  $p=0.202$ ). As well, the moduli of the fresh leaflets were not statistically different ( $p=0.333$ ).

5           Decellularized aortic leaflets failed at the same load and maximum stress as did the fresh tissue. The failure load of pulmonary leaflets rose slightly but not significantly, but there was almost a tripling of the stress at failure.

10           The stiffening of pulmonary leaflets observed with load testing was again reflected when the tissue was loaded to failure. The modules of pulmonary leaflets taken to failure increased 2.6-fold after  
15           decellularization; in contrast, the elastic modules of the decellularized aortic leaflets declined slightly ( $45.5 \pm 6.2$  MPa vs.  $38.3 \pm 5.2$  Mpa).

*Tissue calcification.* The kinetics of calcification of porcine heart valve tissues at 1, 2, and 4 months of implantation are presented in Fig. 4.  
20           Glutaraldehyde-fixed porcine pulmonary heart valve tissues appeared especially prone to calcify in the subdermal rat model. The pulmonary leaflets and vascular conduit calcified more rapidly than their aortic valve counterparts, the fixed pulmonary leaflets  
25           calcifying most rapidly of all tissues examined. Furthermore, glutaraldehyde-fixed pulmonary leaflets attained the highest tissue content of calcium over the four months of subcutaneous implantation. In general,

the fixed vascular conduits calcified more slowly than the leaflets from the same valve type and the final calcium content was significantly lower ( $p < 0.05$  for both aortic and pulmonary valves) at 4 months.

5           The impact of depopulation on heart valve calcification seen as a slowing of the calcification of fixed or non-fixed tissue (pulmonary leaflet) or a plateauing of calcification after two months of implantation (aortic leaflet, aortic conduit, pulmonary  
10           artery). The plateau phenomenon was seen in either the unfixed tissues or in those which were decellularized prior to glutaraldehyde fixation. No statistically significant difference in the calcification of aortic conduit was found among the treatment groups over the 4  
15           months of implantation. Calcification of decellularized aortic conduit proceeded more quickly than fixed tissue for the first 2 months of implant, and then leveled off while fixed conduit calcium content continued to rise. An attenuating effect on the increase in pulmonary  
20           artery calcium content was also observed relative to either fixed tissue group.

          Aortic and pulmonary leaflets had somewhat different responses to decellularization. Decellularization of aortic leaflets with subsequent  
25           fixation resulted in lower calcium content ( $73 \pm 17$  mg  $\text{Ca}^{2+}$ /g tissue) than aortic leaflets which were not fixed ( $121 \pm 8$  mg/g,  $p < 0.05$ ). Although tissue was not available from the 4 month time point, in pulmonary leaflets, the decellularized tissue per se tended to have lower

calcium content ( $152 \pm 5$  vs.  $101 \pm 34$  mg/g at 2 months of implantation).

*Histologic examinations.* Areas of decellularized porcine aortic leaflet at 1 month can be shown  
5 free of endogenous cells within the tissue matrix as well as having no deposits. Since measured tissue calcium in this group was  $60 \pm 14$  mg/g, calcific deposits were found only in localized areas. When examined  
10 further using von Kossa's stain, such areas were evident. Within these areas calcium deposits appeared in association with nonspecific structures. In contrast, the early calcification of nondecellularized glutaraldehyde-fixed tissues was always associated with cell nuclei. The increasing extent of involvement of  
15 the leaflet tissue with time of implant is evident from a 1, 2, and 4 month sequence. The midsubstance of the leaflets calcified early, while the margins calcified later. In either the aortic or pulmonary valve vascular components, calcified areas typically remained at the  
20 periphery of the implant, and only infrequently did tissues show evidence of mineralization of the midsubstance of the implant.

\* \* \*

25 All documents cited above are hereby incorporated in their entirety by reference.

One skilled in the art will appreciate from a reading of this disclosure that various changes in form

and detail can be made without departing from the true scope of the invention.

WHAT IS CLAIMED IS:

1. A method of producing a decellularized tissue comprising:

i) contacting a biological tissue with a hypotonic solution under conditions such that lysis of cells of said tissue is effected, and

ii) contacting the tissue resulting from step (i) with nuclease under conditions such that nucleic acid is degraded,

said decellularized tissue thereby being produced.

2. The method according to claim 1 further comprising contacting the decellularized tissue with a physiologically isotonic solution.

3. The method according to claim 1 further comprising fixing said decellularized tissue.

4. The method according to claim 1 wherein said decellularized tissue is at least 70% decellularized.

5. The method according to claim 1 wherein the tissue is a mammalian tissue.

6 The method according to claim 1 wherein the tissue is a heart valve, tendon, ligament, artery, vein, diaphragm, pericardium, umbilical cord, facia, dura mater, tympanic membrane, or portion thereof.

7. The method according to claim 6 wherein said tissue is a heart valve.

8. A decellularized tissue produced according to the method of claim 1.

5           9. The tissue according to claim 8 wherein said tissue is a heart valve, tendon, ligament, artery, vein, diaphragm, pericardium, umbilical cord, facia, dura mater, tympanic membrane, or portion thereof.

10           10. The tissue according to claim 9 wherein said tissue is a heart valve.

11. The tissue according to claim 8 wherein the tissue is at least 70% decellularized.

12. The tissue according to claim 8 wherein the tissue is fixed.

15           13. A method of mitigating mineralization of a biological tissue transplant comprising:

i) contacting a biological tissue with a hypotonic solution under conditions such that lysis of cells of said biological tissue is effected, and

20           ii) contacting the tissue resulting from step (i) with nuclease under conditions such that nucleic acid is degraded,



wherein the tissue resulting from step (ii) is decellularized and said mitigation is thereby effected.

14. The method according to claim 13 wherein  
5 mineralization is mitigated by at least 30 percent relative to non-decellularized tissue.

15. A method of reducing the immunogenicity of a biological tissue transplant comprising:

i) contacting a biological tissue with a  
10 hypotonic solution under conditions such that lysis of cells of said biological tissue is effected, and  
ii) contacting the tissue resulting from step (i) with nuclease under conditions such that nucleic acid is degraded,

15 wherein the tissue resulting from step (ii) is decellularized and said reduction in immunogenicity is thereby effected.

Fig. 1




Fig 2

A

B




Fig. 3





Fig 4

**In Vivo Calcification of Porcine Heart Valve Tissues**

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/07072

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61F 2/02

US CL : 623/11

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 8/11, 18, 94; 128/898; 435/1, 240, 240.1, 240.2, 241, 243; 623/1, 2, 11, 12, 66

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
APS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category*     | Citation of document, with indication, where appropriate, of the relevant passages            | Relevant to claim No.                       |
|---------------|---|---|
| X<br>---<br>Y | US 5,613,982 A (GOLDSTEIN) 25 March 1997, col. 5 line 27 to col. 7 line 67; and Examples 1-7. | 1-3, 5-10, 13, 15<br>-----<br>4, 11, 12, 14 |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

|   |     |  |
|---|-----|--|
| * Special categories of cited documents:  | *T  | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| *A* document defining the general state of the art which is not considered to be of particular relevance  | *X* | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| *E* earlier document published on or after the international filing date  | *Y* | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *Z* | document member of the same patent family  |
| *O* document referring to an oral disclosure, use, exhibition or other means  |     |  |
| *P* document published prior to the international filing date but later than the priority date claimed  |     |  |

Date of the actual completion of the international search

22 JULY 1998

Date of mailing of the international search report

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FRANK CUDDIHY

Telephone No. (703) 308-2996


Form PCT/ISA/210 (second sheet)(July 1992)\*



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |           |  |
|--|--|-----------|--|
| (51) International Patent Classification <sup>6</sup> :<br><b>A61F 2/02</b>  |  | <b>A1</b> | (11) International Publication Number:<br><b>WO 98/46165</b>   |
|  |  |           | (43) International Publication Date: 22 October 1998 (22.10.98)  |
| (21) International Application Number: PCT/US98/07072<br>(22) International Filing Date: 10 April 1998 (10.04.98)<br>(30) Priority Data:<br>08/838,852          11 April 1997 (11.04.97)          US<br>(71) Applicant: CRYOLIFE, INC. [US/US]; 1655 Robert Boulevard, N.W., Kennesaw, GA 30144 (US).<br>(72) Inventors: GOLDSTEIN, Steven; 2939 Greenbrook Way, Atlanta, GA 30345 (US). BLACK, Kirby, S.; 1371 Peppergrass Trail, Acworth, GA 30301 (US).<br>(74) Agent: WILSON, Mary, J.; Nixon & Vanderhye P.C., 8th floor, 1100 North Glebe Road, Arlington, VA 22201-4714 (US). |  |           | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.<br/>         Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |

(54) Title: TISSUE DECELLULARIZATION

*In Vivo* Calcification of Porcine Heart Valve Tissues

## (57) Abstract

The present invention relates, in general, to tissue decellularization and, in particular to a method of treating tissues, for example, heart valves, tendons and ligaments, so as to render them acellular and thereby limit mineralization and/or immunoreactivity upon implementation *in vivo*.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |



## TISSUE DECELLULARIZATION

TECHNICAL FIELD

The present invention relates, in general, to tissue decellularization and, in particular to a method of treating tissues, for example, heart valves, ligaments and tendons, so as to render them acellular and thereby limit mineralization and/or immunoreactivity upon implantation in vivo.

BACKGROUND

Cardiac valve disorders can be serious and in fact are often fatal. Treatment may require replacement of the valve with a prosthetic valve - mechanical or bioprosthetic. Bioprosthetic valves typically include a leaflet portion and a vascular conduit portion, both generally of a biological material, and possibly a stent.

While bioprosthetic valves have a number of advantages over mechanical valves, including a lower risk of complications resulting from thrombus formation, they are associated with a higher risk of mineralization. This increased risk significantly limits the durability of the replacement valve. The present invention provides a method of rendering tissues, including heart valves, resistant to mineralization while preserving biomechanical properties

of the tissue. The present invention also provides a method of reducing immunoreactivity of transplanted tissues which are not fixed by chemical or physical means, or combinations thereof, prior to implantation.

5

# OBJECT AND SUMMARY OF THE INVENTION

It is a general object of the invention to provide a method treating tissue so as to limit mineralization and/or immunoreactivity post implantation.

10 It is another object of the invention to provide a method of decellularizing a tissue and thereby enhancing its durability and/or reducing its immunoreactivity.

It is a further object of the invention to provide a tissue, for example, a heart valve bioprosthesis, that retains mechanical integrity, is resistant to  
15 calcification and is characterized by reduced immunoreactivity upon implantation.

The foregoing objects are met by the present invention which provides a method of effecting decellularization of tissues, including heart valve  
20 tissues (eg leaflets and valve associated vascular conduit). The method comprises contacting the tissue to be decellularized with a hypotonic solution under conditions such that cell lysis occurs, and subsequently  
subjecting the tissue to nuclease treatment under  
25 conditions such that the tissue is rendered histologically acellular.

Further objects and advantages of the present invention will be clear from the description that follows.

#### BRIEF DESCRIPTION OF THE DRAWINGS

5           Figures 1A and B show the effect of decellularization on the extensibility of and elastic modulus of aortic and pulmonary leaflets.

          Figures 2A and B show the effect of decellularization on rates of stress-relaxation of  
10           aortic and pulmonary leaflets.

          Figures 3A, B and C show the effect of decellularization on failure load, maximum stress and elastic modulus of aortic and pulmonary leaflets.

          Figures 4A, B, C and D show the effect of  
15           decellularization on calcification of porcine heart aortic and pulmonary heart valve tissues.

#### DETAILED DESCRIPTION OF THE INVENTION

          The present invention relates, in one embodiment, to a method of rendering a biological tissue acellular.  
20           The method comprises exposing the tissue to a hypotonic solution under conditions such that cell lysis results, and subjecting the resulting tissue to nuclease

treatment so as to remove nucleic acids and associated phosphorous-containing groups which may bind calcium. Nuclease treatment effectively stops cell replication and protein synthesis. In a preferred aspect of this embodiment, the tissue is rendered essentially acellular, the term "essentially" meaning having at least 70% fewer cells than the naturally occurring biological material. The extent of decellularization can be determined histochemically, for example, by staining the tissue with hematoxylin and eosin using standard techniques. Immunohistochemical staining can also be used, for example, to visualize cell specific markers such as smooth muscle actin and histocompatibility antigens - an absence of such markers being a further indication of decellularization.

In accordance with the present method, the biological tissue is, preferably, first washed in a solution of a bioburden reducing agent, such as an antibiotic. The tissue can then be decellularized immediately or it can be cryopreserved. Cryopreserved tissue is thawed prior to decellularization under conditions such that the cryoprotectant is eliminated and toxicity resulting therefrom thereby avoided. Appropriate thawing conditions are well known in the art. The tissue (fresh or thawed cryopreserved) is then placed in hypotonic solution in order to effect cell lysis. Appropriate solutions include water or a solution having a solute (eg a salt such as NaCl) concentration of up to 80 milliosmolar (for example, a

10-20 or 20-40 mM NaCl solution). Lysis can be effected, for example, at a temperature in the range of 30°C to 40°C, preferably 37°C, advantageously in an atmosphere of 5% CO<sub>2</sub>, for example, for about 4 to  
5 24 hours. The tissue is then transferred to a nuclease solution (eg DNAase- and/or RNAase-containing) and incubated, for example, at a temperature in the range of about 30°C to 40°C, preferably 37°C, advantageously in an atmosphere of 5% CO<sub>2</sub>, for example, for about 4 to  
10 24 hours. Subsequently, the tissue is transferred to a solution that can maintain tissue structural integrity, for example, a physiologically normal (isotonic) solution such as a cell culture medium, eg DMEM. Cell lysis can continue during maintenance of the tissue in  
15 the physiologically normal solution and thus the tissue can be removed from the lytic/nuclease solutions before 70% decellularization has been achieved.

Tissues that have been decellularized can be terminally sterilized using any of a variety of  
20 sterilants. For example, the tissue can be subjected to gamma irradiation, ethylene oxide, peracetic acid, β-propiolactone, povidone-iodine, or UV irradiation in the presence or absence of photosensitizers. Appropriate conditions for effecting terminal  
25 sterilization are well known in the art.

Biological tissues suitable for use in the present method include those appropriate for implantation into humans or animals. Tissues can be human or non-human (eg bovine, porcine or non-human primate) in origin. As

indicated above, the tissues can be fresh or cryopreserved. In either case, the tissue is decellularized prior to any fixation. While the present invention is exemplified by reference to heart valve  
5 leaflets, the decellularization method is applicable to other tissues as well, including tendons, ligaments, fascia, arteries, veins, diaphragm, pericardium, umbilical cords, dura mater or tympanic membranes.

Upon completion of decellularization, the  
10 biological tissue can be processed and/or fabricated as appropriate depending on the ultimate use of the tissue. Any fixation of the decellularized tissue can be effected using art-recognized techniques, including glutaraldehyde fixation. Unfixed tissue, however, can  
15 also be used. Unfixed tissue can be impregnated with any of a variety of agents including those that stimulate recellularization upon implantation of the decellularized tissue in vivo. Examples of such agents include growth factors, adhesion factors, such as  
20 glycosaminoglycans, and soluble extracellular matrix glycoproteins such as fibronectin, laminin, vitronectin, etc. Other agents that can be used include those that augment hemocompatibility, thrombomodulators, and antibiotics. Appropriate impregnation techniques are  
25 known in the art. When the tissue is a heart valve, fabrication with a biological or non-biological stent can be effected using standard protocols.

Bioprostheses produced in accordance with the present invention can be used as replacements for

defective tissues in mammals, particularly humans. Methods of effecting the replacement of, for example, heart valves, tendons, ligaments, vessels, etc., are well known in the art.

5           Tissue decellularized in accordance with the present invention is subject to less mineralization (eg calcification) in vivo than non-treated tissue. Decellularization also results in a tissue that is reduced in immunogenicity.

10           Certain aspects of the present invention are described in greater detail in the non-limiting Examples that follow. While the decellularization methodology of the present invention and that of USP 5,595,571 are distinct, it will be appreciated that certain details of  
15           that disclosure are equally applicable here, including source of biological tissues, methods of monitoring extent of decellularization and methods of processing and fabrication post decellularization. Accordingly, USP 5,595,571 is incorporated in its entirety by  
20           reference.

#### EXAMPLE I

##### Decellularization of Leaflets and Whole Valves

25           The following solutions are utilized in the protocols that follow:

1M Tris pH 7.6: To 80ml deionized water add  
11.21gm Tris, adjust pH to 7.6 with 1N NaOH and bring  
volume to 100ml and store at 4°C.

5 1M CaCl<sub>2</sub>: To 20ml deionized water add 2.22gm CaCl<sub>2</sub>  
and store at 4°C.

1M MgCl<sub>2</sub>: To 10ml deionized water add 2.033gm MgCl<sub>2</sub>  
and store at 4°C.

10 DNase I Solution: To 4.95ml sterile water add 5ml  
glycerol (final conc 50%), 20mg DNase I (Sigma D5025)  
(final conc 2mg/ml), and 50 µl 1M CaCl<sub>2</sub> (final conc  
5 mM). Aliquot 1ml to chilled labeled 1.5ml microfuge  
tubes and store at -20°C.

15 RNase A Solution: To 10ml sterile water add 100mg  
RNase A, and mix to dissolve. Aliquot 500µl of solution  
to each of 20 prechilled 1.5ml microfuge tubes and store  
at -20°C.

20 Nuclease Solution: To 93.66ml sterile water, add  
4.8ml 1M Tris pH 7.6 (final 48mM), 288µl 1M MgCl<sub>2</sub> (final  
conc 2.88mM), 96µl 1M CaCl<sub>2</sub> (final conc .96mM), filter  
sterilize using 0.2 micron filter, add 960µl 2mg/ml  
DNase I (final conc 19.2 µg/ml) 192µl 10mg/ml RNase A  
(final conc 19.2 µg/ml).



Decellularization of leaflets

## DAY 1

5 A valve is removed from a liquid nitrogen freezer and submerged in a 37°C water bath for approximately 15 min. Under sterile conditions, the valve is removed from the packaging and placed in a sterile 7oz. specimen cup with approximately 50ml of lactate-ringer 5% dextrose (LRD5) solution for 15 min. at room temperature. The valve is dissected by making a single cut down the commissure located between the left and right coronary arteries. The valve is laid open with the mitral valve leaflet up, the left coronary leaflet to the left, the right coronary leaflet to the right, and the non-coronary leaflet in the middle. The leaflets are dissected free of the valve as close to the conduit wall as possible and placed in separate labeled 15ml conical centrifuge tubes filled with 10ml LRD5 solution for 10 minutes at room temperature. The leaflets are moved to second labeled 15ml conical centrifuge tubes filled with 10ml LRD5 solution and allowed to stand for 10 minutes at room temperature. The leaflets then are moved to third labeled 15ml conical centrifuge tubes filled with 10ml sterile water and placed in an incubator at 37°C 5% CO<sub>2</sub> for 2 hours. The leaflets are placed in 6-well culture plates and weighted down with sterile glass rings. 5 ml nuclease solution is added to each well and the leaflets incubated overnight at 37°C 5% CO<sub>2</sub>.

## DAY 2

The nuclease solution is removed and 5ml of DMEM is added to each well and the leaflets are returned to the incubator.

## 5 DAY 3-16

The medium is changed every other day for two weeks.

Alternative procedure for whole valves

10 If valves have been cryopreserved, they are thawed and washed as above; if valves are fresh, they are washed once in 80ml of LRD5 for 15 minutes in a 7oz sterile specimen cup.

15 After the valve is washed, it is transferred to a 7oz sterile specimen cup containing about 80ml of sterile H<sub>2</sub>O and placed in the 37°C 5% CO<sub>2</sub> incubator for 4 hours.

The valve is removed to a 7oz sterile specimen cup containing about 80ml nuclease solution and returned to the incubator overnight.

## 20 DAY 2

The valve is removed to a 7oz sterile specimen cup containing about 80ml (ALT+) solution (containing netilmicin, 54µg/ml; lincomycin, 131µg/ml; cefotaxime, 145µg/ml; vancomycin, 109µg/ml; rifampin, 65µg/ml; 3 fluconazole, 100µg/ml; and amphotericin B, 84µg/ml).

11

## DAY 3-16

The medium is changed every other day for two weeks using ALT+ solution for the first week and DMEM for the second.

- 5           The foregoing procedures are open culture procedures. Thus the specimen cup lids are loosened when placed in the incubator.

## EXAMPLE II

Experimental details:

- 10           Porcine heart valves. Porcine hearts were obtained from market weight pigs (> 120 kg). After rinsing in sterile phosphate buffered saline, the hearts were field dissected (apex removed) and shipped at 4°C in sterile PBS. All hearts arrived within 24 hr of animal
- 15           slaughter. Aortic and pulmonary valves were dissected as roots. These tissues were subjected to a bioburden reduction step of incubation in a mixture of antibiotics and antimycotics for 48 hr at 48°C. The disinfected tissues were either cryopreserved (10% (v/v) DMSO and
- 20           10% (v/v) fetal bovine serum, -1°C/min) or were decellularized by a procedure involving treatment with hypotonic medium followed by digestion with a mixture of deoxyribonuclease I and ribonuclease A. After 12 days, the decellularized valves were either cryopreserved as
- 3           above or chemically fixed in 0.35% (w/v) glutaraldehyde

at 2 mmHg in phosphate buffered saline (pH 7.4) for a total of 7 days; the low pressure fixation ensures maintenance of the natural crimp of the collagen matrix. The fixed tissues were not cryopreserved, but were  
5 stored in 0.35% glutaraldehyde solution.

Prior to any examination (calcification, biomechanics, histology), the cryopreserved tissues were thawed rapidly to prevent ice-recrystallization by immersion of the packaged tissue in a 37°C water bath.  
10 Cryopreservation medium was eluted from the thawed valves with 500 ml of lactated-Ringers solution containing 5% dextrose. The glutaraldehyde-fixed tissues were washed three times each with 200 ml of normal saline.

15 *In vivo static calcification.* Calcification of treated tissues was assessed in vivo by subdermal implantation in rats. Weanling male, Sprague-Dawley rats were obtained from Charles Rivers Laboratories. After one week equilibration, animals averaged  $136 \pm 18$   
20 g in weight. The heart valves were dissected to provide aortic and pulmonary leaflets and vascular conduit sections, each 0.5 cm square. With the rats under ketamine and xylazine (10 mg/kg and 5 mg/kg, respectively, IP) anesthesia, and following preparation  
25 of a sterile field, 2 cm diameter pouches were formed in the dorsal subcutaneous, four per animal, and sections of tissues inserted. Incisions

were closed with stainless steel staples. The rats were allowed to recover and were then permitted free access to food and water. Tissue samples were recovered at 1, 2, and 4 months post-implantation for  
5 determination of calcium content.

*Method for calcium determination in tissue samples.*  
Recovered tissues were washed in sterile calcium and magnesium-free phosphate buffered saline, three times 10 ml each. Wet weight was measured, and after mincing,  
10 the pieces were dried overnight in a centrifugal evaporator (Savant Speed-Vac). After recording dry weight the tissues were digested in 10 ml of 25% (v/v) HNO<sub>3</sub> for at least 24 hr at 70°C. An aliquot of the digest solution was diluted 10-fold in 0.2 N HCl  
15 containing 1% (w/v) lanthanum nitrate. Finally, calcium content was measured using a Perkin-Elmer 300 atomic absorption spectrometer calibrated with a certified calcium standard from SPEX Plasma Standards (Cat. PLCA2-3Y. Response in this system was linear between  
20 0.2-20 µg/ml.

*Biomechanics testing.* Aortic and pulmonary leaflets were die cut in the circumferential dimension to provide "dog-bone"-shaped specimens, 0.5 cm wide at midsubstance. Thickness of each sample was derived from  
25 the average of three measurements taken with a low mass pin attached to a conductance circuit and digital

caliper. Leaflets were mounted in specially designed clamps with a standard gauge length of 1 cm. All testing was carried out with the tissue in Hank's balanced salt solution maintained at  $37 \pm 2^\circ\text{C}$ . Each specimen was preconditioned to a load of 150 g until successive load-elongation curves were superimposable (~20 cycles). The following measurements were then taken: 1) low-load elongation to derive stress-strain relationships while imposing up to 150 g load on the tissue at an extension rate of 10 mm/min, a rate which reflects previously reported studies of leaflet biomechanics (Leesson-Dietrich et al, J. Heart Valve Disease 4:88 (1995)); 2) examination of viscoelastic properties of the specimens in a stress-relaxation study (tissue elongated to a load of 150 g and following residual loads for up to 1000 sec) - both the % of initial load remaining at these time points as well as the rate of stress-relaxation (i.e., the slope of the percent stress remaining versus time) were determined; and 3) ultimate uniaxial tensile testing to tissue failure. At least 8 specimens of each tissue type were examined.

*Histochemistry.* Samples of fresh and explanted tissues were immersed in 10% sucrose solution for 4-18 hr at  $4^\circ\text{C}$ . After brief fixation in 10% formalin, the pieces were placed in molds and frozen in OCT using a liquid nitrogen bath. Cryosections, 6-10  $\mu\text{m}$  thick, were cut using an IEC cryostat (Needham Heights, MA).

Sections were then stained either with hematoxylin and eosin or stained specifically for calcium according to the method of von Kossa (Theory and Practice of Histological Techniques, edited by Bancroft and Stephens, Churchill Livingstone, Edinburgh (1990)). Sections were viewed and photographed using a Nikon Optiphot microscope.

*Statistics.* Statistical differences in the group means of biomechanical parameters was assessed by independent t-tests. A p value of 0.05 was chosen as the level of significant differences. Calcium data were analyzed according to ANOVA testing carried out with the statistical program for the IBM-PC, SPSS-PC.

### Results

*Biomechanics.* Low load testing - extensibility and low modulus. The biomechanical properties of strips of aortic and pulmonary porcine heart valve leaflets were compared between fresh-cryopreserved and decellularized-cryopreserved tissues. Fresh aortic and pulmonary leaflets were found to have significant differences in extensibility; pulmonary leaflets had extension 2.3-fold greater than aortic leaflets ( $p < 0.01$ ). However, the elastic modulus of these tissues were not different pre-decellularization ( $10.6 \pm 1.1$  vs.  $9.15 \pm 0.64$ ,  $p = 0.255$ , Fig. 1). With decellularization, the extensibility of the two leaflet type became indistinguishable ( $30.4 \pm 2.5$

vs.  $30.2 \pm 3.3$ ,  $p=0.981$ ). The elastic modulus of the aortic leaflets was unchanged by decellularization ( $p=ns$  (not significant)), as compared to the fresh tissue). In contrast, pulmonary leaflet tissues was markedly  
5 stiffened by decellularization, with the elastic modulus rising by 660%, ( $p<0.05$ ). As a result, the elastic modulus of decellularized pulmonary tissue was 550% greater than that of the decellularized aortic leaflet.

Stress-relaxation testing. The initial (10 sec)  
10 and the final (1,000 sec) rates of stress-relaxation for fresh aortic and pulmonary leaflets were comparable and not statistically different ( $p=0.103$  and  $p=0.115$ , respectively, Fig. 2). For decellularized  
15 tissues, only the initial rate of stress-relaxation or aortic leaflets was obtained; this was no different from the fresh tissue value. The increased stiffening of the pulmonary leaflets with decellularization which was observed with low-load testing was reflected by a higher  
20 final level of stress remaining (increase from  $64.1 \pm 2.18\%$  to  $81.5 \pm 2.5\%$ ). The relaxation slope for the pulmonary leaflets were reciprocally changed by decellularization, decreasing from  $9.8 \pm 0.8$  in the fresh tissue to  $4.7 \pm 1.5$  in the treated tissue.

Ultimate tensile testing - failure load, maximum  
25 stress, and elastic modulus (Fig. 3). In fresh tissues the aortic leaflets failed a twice the load as did the pulmonary valve tissue ( $p<0.001$ ). However, there



was no statistical difference maximum stress at failure of the aortic and pulmonary leaflets ( $8.0 \pm 1.2$  MPa vs.  $6.0 \pm 0.9$ ,  $p=0.202$ ). As well, the moduli of the fresh leaflets were not statistically different ( $p=0.333$ ).

5       Decellularized aortic leaflets failed at the same load and maximum stress as did the fresh tissue. The failure load of pulmonary leaflets rose slightly but not significantly, but there was almost a tripling of the stress at failure.

10       The stiffening of pulmonary leaflets observed with load testing was again reflected when the tissue was loaded to failure. The modules of pulmonary leaflets taken to failure increased 2.6-fold after  
15       decellularization; in contrast, the elastic modules of the decellularized aortic leaflets declined slightly ( $45.5 \pm 6.2$  MPa vs.  $38.3 \pm 5.2$  Mpa).

20       *Tissue calcification.* The kinetics of calcification of porcine heart valve tissues at 1, 2, and 4 months of implantation are presented in Fig. 4. Glutaraldehyde-fixed porcine pulmonary heart valve tissues appeared especially prone to calcify in the subdermal rat model. The pulmonary leaflets and vascular conduit calcified more rapidly than their aortic valve counterparts, the fixed pulmonary leaflets  
25       calcifying most rapidly of all tissues examined. Furthermore, glutaraldehyde-fixed pulmonary leaflets attained the highest tissue content of calcium over the four months of subcutaneous implantation. In general,

the fixed vascular conduits calcified more slowly than the leaflets from the same valve type and the final calcium content was significantly lower ( $p < 0.05$  for both aortic and pulmonary valves) at 4 months.

5           The impact of depopulation on heart valve calcification seen as a slowing of the calcification of fixed or non-fixed tissue (pulmonary leaflet) or a plateauing of calcification after two months of implantation (aortic leaflet, aortic conduit, pulmonary  
10           artery). The plateau phenomenon was seen in either the unfixed tissues or in those which were decellularized prior to glutaraldehyde fixation. No statistically significant difference in the calcification of aortic conduit was found among the treatment groups over the 4  
15           months of implantation. Calcification of decellularized aortic conduit proceeded more quickly than fixed tissue for the first 2 months of implant, and then leveled off while fixed conduit calcium content continued to rise. An attenuating effect on the increase in pulmonary  
20           artery calcium content was also observed relative to either fixed tissue group.

          Aortic and pulmonary leaflets had somewhat different responses to decellularization. Decellularization of aortic leaflets with subsequent  
25           fixation resulted in lower calcium content ( $73 \pm 17$  mg  $\text{Ca}^{2+}$ /g tissue) than aortic leaflets which were not fixed ( $121 \pm 8$  mg/g,  $p < 0.05$ ). Although tissue was not available from the 4 month time point, in pulmonary leaflets, the decellularized tissue per se tended to have lower

calcium content ( $152 \pm 5$  vs.  $101 \pm 34$  mg/g at 2 months of implantation).

*Histologic examinations.* Areas of decellularized porcine aortic leaflet at 1 month can be shown  
5 free of endogenous cells within the tissue matrix as well as having no deposits. Since measured tissue calcium in this group was  $60 \pm 14$  mg/g, calcific deposits were found only in localized areas. When examined  
10 further using von Kossa's stain, such areas were evident. Within these areas calcium deposits appeared in association with nonspecific structures. In contrast, the early calcification of nondecellularized glutaraldehyde-fixed tissues was always associated with cell nuclei. The increasing extent of involvement of  
15 the leaflet tissue with time of implant is evident from a 1, 2, and 4 month sequence. The midsubstance of the leaflets calcified early, while the margins calcified later. In either the aortic or pulmonary valve vascular components, calcified areas typically remained at the  
20 periphery of the implant, and only infrequently did tissues show evidence of mineralization of the midsubstance of the implant.

\* \* \*

25 All documents cited above are hereby incorporated in their entirety by reference.

One skilled in the art will appreciate from a reading of this disclosure that various changes in form

and detail can be made without departing from the true scope of the invention.

**SUBSTITUTE SHEET (RULE 26)**

WHAT IS CLAIMED IS:

1. A method of producing a decellularized tissue comprising:

i) contacting a biological tissue with a hypotonic solution under conditions such that lysis of cells of said tissue is effected, and

ii) contacting the tissue resulting from step (i) with nuclease under conditions such that nucleic acid is degraded,

said decellularized tissue thereby being produced.

2. The method according to claim 1 further comprising contacting the decellularized tissue with a physiologically isotonic solution.

3. The method according to claim 1 further comprising fixing said decellularized tissue.

4. The method according to claim 1 wherein said decellularized tissue is at least 70% decellularized.

5. The method according to claim 1 wherein the tissue is a mammalian tissue.

6 The method according to claim 1 wherein the tissue is a heart valve, tendon, ligament, artery, vein, diaphragm, pericardium, umbilical cord, facia, dura mater, tympanic membrane, or portion thereof.

5

7. The method according to claim 6 wherein said tissue is a heart valve.

8. A decellularized tissue produced according to the method of claim 1.

5 9. The tissue according to claim 8 wherein said tissue is a heart valve, tendon, ligament, artery, vein, diaphragm, pericardium, umbilical cord, fascia, dura mater, tympanic membrane, or portion thereof.

10 10. The tissue according to claim 9 wherein said tissue is a heart valve.

11. The tissue according to claim 8 wherein the tissue is at least 70% decellularized.

12. The tissue according to claim 8 wherein the tissue is fixed.

15 13. A method of mitigating mineralization of a biological tissue transplant comprising:

- i) contacting a biological tissue with a hypotonic solution under conditions such that lysis of cells of said biological tissue is effected, and
- 20 ii) contacting the tissue resulting from step (i) with nuclease under conditions such that nucleic acid is degraded,

wherein the tissue resulting from step (ii) is decellularized and said mitigation is thereby effected.

5 14. The method according to claim 13 wherein mineralization is mitigated by at least 30 percent relative to non-decellularized tissue.

15. A method of reducing the immunogenicity of a biological tissue transplant comprising:

10 i) contacting a biological tissue with a hypotonic solution under conditions such that lysis of cells of said biological tissue is effected, and

ii) contacting the tissue resulting from step (i) with nuclease under conditions such that nucleic acid is degraded,

15 wherein the tissue resulting from step (ii) is decellularized and said reduction in immunogenicity is thereby effected.

Fig. 1B





Fig. 1A





2/5

Fig. 2B




Fig. 2A




Fig. 3C




Fig. 3B





Fig. 3A



4/5

Fig. 4B

*In Vivo* Calcification of Porcine  
Heart Valve Tissues





Fig. 4A

*In Vivo* Calcification of Porcine  
Heart Valve Tissues



SUBSTITUTE SHEET (RULE 26)

Fig. 4D



In Vivo Calcification of Porcine  
Heart Valve Tissues

Fig. 4C

In Vivo Calcification of Porcine  
Heart Valve Tissues

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/07072

|  |   |  |
|--|---|--|
| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>IPC(6) : A61P 2/02<br>US CL : 623/11<br>According to International Patent Classification (IPC) or to both national classification and IPC  |   |  |
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>U.S. : 8/11, 18, 94; 128/898; 435/1, 240, 240.1, 240.2, 241, 243; 623/1, 2, 11, 12, 66<br><br>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched<br><br>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>APS |   |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>  |   |  |
| Category*  | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.  |
| X<br>---<br>Y  | US 5,613,982 A (GOLDSTEIN) 25 March 1997, col. 5 line 27 to col. 7 line 67; and Examples 1-7.   | 1-3, 5-10, 13, 15<br>-----<br>4, 11, 12, 14  |
| <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.  |   |  |
| *<br>"A"<br>"B"<br>"L"<br>"O"<br>"P"   | Special categories of cited documents:<br>document defining the general state of the art which is not considered to be of particular relevance<br>earlier document published on or after the international filing date<br>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>document referring to an oral disclosure, use, exhibition or other means<br>document published prior to the international filing date but later than the priority date claimed | "T"<br>"X"<br>"Y"<br>"A"<br>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>document member of the same patent family |
| Date of the actual completion of the international search<br>22 JULY 1998  |   | Date of mailing of the international search report<br>11 AUG 1998  |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703) 305-3230  |   | Authorized officer<br>FRANK CUDDIHY<br>Telephone No. (703) 308-2996  |

Form PCT/ISA/210 (second sheet)(July 1992)\*

